Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892945 | 0.90 | GCK (0.63) | GCKKCNH2 | |
| SCHEMBL1107465 | 0.90 | GCK (0.57) | GCKKCNH2 | |
| SCHEMBL1107298 | 0.89 | GCK (0.52) | GCKKCNH2 | |
| SCHEMBL1107452 | 0.88 | GCK (0.54) | GCKKCNH2 | |
| SCHEMBL1140843 | 0.88 | GCK (0.64) | GCKKCNH2 | |
| SCHEMBL10329791 | 0.87 | GCK (0.60) | GCK | |
| SCHEMBL2664258 | 0.85 | MAPT (0.53) | GCK | |
| SCHEMBL2664229 | 0.82 | GCK (0.50) | GCKKCNH2 | |
| SCHEMBL10329775 | 0.82 | GCK (0.51) | GCKKCNH2 | |
| SCHEMBL12742575 | 0.81 | GCK (0.50) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | GCK 3/4885KCNH2 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.